Floatz logo

1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER

Cancer Of Unknown Primary Site

Mayo Clinicprotein_peptidePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

18 Active assets in the Cancer Of Unknown Primary Site cohort.

Asset / SponsorPhaseRating
Nepenthe
M.D. Anderson Cancer Center
Phase 4BBB
Amifostine
M.D. Anderson Cancer Center
Phase 4BBB
Etoposide
University of California, Davis
Phase 2/3BBB
Dexasone
Alliance for Clinical Trials in Oncology
Phase 3BBB
Xaliplatin
Alliance for Clinical Trials in Oncology
Phase 2BBB

View all 50 →

Same molecule, other indications

1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER is also rated in:

psoriasisDormant
BBB
Indicative · Phase 4
76 / 100
View asset →
skin carcinomaDormant
BB
Indicative · Phase 4
67 / 100
View asset →
sciaticaDormant
BB
Indicative · Phase 2/3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →